OTIC - Otonomy, Inc.
| Previous Close | 2.9100 |
| Open | 2.9100 |
| Bid | 2.9200 x 1100 |
| Ask | 3.0500 x 1100 |
| Day's Range | 2.8563 - 3.0000 |
| 52 Week Range | 1.5000 - 4.8500 |
| Volume | 154,382 |
| Avg. Volume | 185,881 |
| Market Cap | 91.136M |
| Beta (3Y Monthly) | 2.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6450 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
- Zacks•8 days ago
Will Otonomy Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Otonomy.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 Otonomy Inc Earnings Call
- Simply Wall St.•13 days ago
Those Who Purchased Otonomy Shares Three Years Ago Have A 84% Loss To Show For It
Otonomy, Inc. (NASDAQ:OTIC) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking declineRead More...
- GlobeNewswire•14 days ago
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, March 05, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire•15 days ago
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase.
- GlobeNewswire•22 days ago
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd Annual MidWinter Meeting, to be held February 9-13, in Baltimore. “Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss and otoprotection," said Kathie Bishop, Ph.D., chief scientific officer of Otonomy.
- Simply Wall St.•2 months ago
An Examination Of Otonomy, Inc. (NASDAQ:OTIC)
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...
- GlobeNewswire•2 months ago
Otonomy Provides Corporate and Product Pipeline Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. The company expects to have clinical trial results for three programs in 2020 including the previously announced Phase 3 trial of OTIVIDEX in Ménière’s disease in the first half of 2020, Phase 1/2 trial of OTO-313 in tinnitus patients in the first half of 2020, and Phase 1/2 trial of OTO-413 in patients with hearing loss in the second half of 2020. The company finished 2018 with approximately $97 million in cash, cash equivalents and short term investments that includes proceeds from a $15 million term loan from Oxford Finance LLC completed in December 2018.
- GlobeNewswire•2 months ago
Otonomy to Present at the J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 02, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.•3 months ago
Is Otonomy Inc (NASDAQ:OTIC) Excessively Paying Its CEO?
David Weber has been the CEO of Otonomy Inc (NASDAQ:OTIC) since 2010. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a Read More...
- GlobeNewswire•4 months ago
Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO, Nov. 15, 2018 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that.
- GlobeNewswire•4 months ago
Report: Developing Opportunities within Control4, Nanometrics, Century Casinos, Steven Madden, Otonomy, and C&J Energy Services — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today is presenting data on the therapeutic potential of OTO-413, an otic sustained-exposure formulation of brain-derived neurotrophic factor (BDNF). “The selection of our OTO-413 presentation as a Neuroscience 2018 Hot Topic acknowledges the increasing interest in better understanding the neuroscience of the inner ear and the importance of Otonomy’s work to address the significant unmet needs of people living with hearing loss as well as other burdensome otologic conditions, such as Ménière’s disease, and tinnitus,” said Kathie Bishop, Ph.D., chief scientific officer of Otonomy.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of OTIC earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Otonomy Inc Earnings Call
- Associated Press•4 months ago
Otonomy: 3Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 41 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•4 months ago
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting.
- GlobeNewswire•5 months ago
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple presentations related to the company's programs in hearing loss and tinnitus at the upcoming Society for Neuroscience (SfN) Annual Meeting, to be held November 3-7, in San Diego. A presentation demonstrating the therapeutic potential of OTO-413, a sustained-exposure otic formulation of brain-derived neurotrophic factor (BDNF), for the repair of cochlear synaptopathy in speech-in-noise hearing difficulties has been selected by SfN as a Neuroscience 2018 Hot Topic. “At Otonomy, we have a singular focus on understanding the neuroscience of the ear and on delivering breakthrough treatments to the millions living with the often debilitating effects of conditions like tinnitus, Ménière’s disease and hearing loss.
- PR Newswire•6 months ago
Oculis Elects Anthony Rosenberg and David A. Weber - Veterans of the Global Pharmaceutical and Eye-care Industries - to its Board of Directors
Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, Ph.D. as Non-Executive Director. "This is an exciting period for Oculis, as we look to advance and expand the clinical development of our lead candidate OC-118, a potential transformative topical treatment for Diabetic Macular Edema (DME).
Simply Wall St.•6 months agoWho Owns Otonomy Inc (NASDAQ:OTIC)?
Every investor in Otonomy Inc (NASDAQ:OTIC) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decreaseRead More...
